Margaret Rose Sketch

Margaret Rose Sketch

Auto-generated profile, based on publicly available information

Margaret Rose Sketch

United Therapeutics Corporation, RTP, NC, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JZJing Zhu
Jing Zhu
TPTejendra Patel
Tejendra Patel
JMJordan Miller
Jordan Miller
CTChad D. Torrice
Chad D. Torrice
MAMehak Aggarwal
Mehak Aggarwal
DCDaniel Crona
Daniel Crona
Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well as a narrow therapeutic index, and therefore requires therapeutic drug monitoring. Germline mutations in cytochrome P450 isoforms 4 and 5 genes (CYP3A4/5) and the ATP-binding cassette B1 gene (ABCB1) may contribute to interindividual tacrolimus PK variability, which may impact clinical outcomes among allogeneic hematopoietic stem cell transplantation (HSCT) patients. In this study, 252 adult patients who received tacrolimus for acute graft versus host disease (aGVHD) prophylaxis after allogeneic HSCT were genotyped to evaluate if germline genetic variants associated with tacrolimus PK and pharmacodynamic (PD) variability. Significant associations were detected between germline variants in CYP3A4/5 and ABCB1 and PK endpoints (e.g., median steady-state tacrolimus concentrations and time to goal tacrolimus concentration). However, significant associations were not observed between CYP3A4/5 or ABCB1 germline variants and PD endpoints (e.g., aGVHD and treatment-emergent nephrotoxicity). Decreased age and CYP3A5*1/*1 genotype were independently associated with subtherapeutic tacrolimus trough concentrations while CYP3A5*1*3 or CYP3A5*3/*3 genotypes, myeloablative allogeneic HSCT conditioning regimen (MAC) and increased weight were independently associated with supratherapeutic tacrolimus trough concentrations. Future lines of prospective research inquiry are warranted to use both germline genetic and clinical data to develop precision dosing tools that will optimize both tacrolimus dosing and clinical outcomes among adult HSCT patients.

26 February 2019 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
JBJill S Bates
Jill S Bates
JAJessica Auten
Jessica Auten
MSMargaret R Sketch
Margaret R Sketch
TPTejendra Patel
Tejendra Patel
SCStephen Michael Clark
Stephen Michael Clark
LALindsey Amerine
Lindsey Amerine
Background: Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the patient activation measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during a patient encounter at the beginning of the patient's treatment for cancer. Methods: This was a single center, prospective, non-randomized, observational clinical study in patients with cancer who required a new chemotherapy plan. A baseline patient activation measure-10 survey was administered and a pharmacy team member met with the patient to complete the first cycle 3CS encounter. Within two business days of that encounter, a second patient activation measure-10 survey was administered, and thus, patients served as their own control. Results: Forty-nine patients who met the inclusion criteria were enrolled, of which 36 completed the study. Mean patient activation measure-10 scores measured at baseline and two business days after the 3CS encounter were significantly different (68.5 ± SD 14.7 vs. 75.0 ± SD 14.3, p = 0.001). This difference persisted when evaluated by gender (female: 70.0 ± SD 14.8 vs. 81.6 ± SD 10.5, p = 0.001; male: 66.1 ± SD 14.8 vs. 70.8 ± SD 14.7, p = 0.022). Conclusion: This study demonstrates that cancer patients had significantly increased patient activation scores after engagement in a 3CS encounter provided by an oncology pharmacy team. Further studies are needed to verify these data in a larger population, different healthcare settings, and to evaluate for patients who have solid tumor malignancies.

1 April 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
PFPaul Forfia
Paul Forfia
RBRaymond l Benza
Raymond l Benza
MDMichele D'Alto
Michele D'Alto
TMTeresa De Marco
Teresa De Marco
JEJean Marie Elwing
Jean Marie Elwing
VMVallerie McLaughlin
Vallerie McLaughlin
Right heart (RH) structure and function are major determinants of symptoms and prognosis in pulmonary arterial hypertension (PAH). RH imaging provides detailed information, but evidence and guidelines on the use of RH imaging in treatment decisions are limited. We conducted a Delphi study to gather expert opinion on the role of RH imaging in decision‐making for treatment escalation in PAH. A panel of 17 physicians with expertise in PAH and RH imaging used three surveys in a modified Delphi process to reach consensus on the role of RH imaging in PAH. Survey 1 used open‐ended questions to gather information. Survey 2 contained Likert scale and other questions intended to identify consensus on topics identified in Survey 1. Survey 3 contained Likert scale questions derived from Survey 2 and summary information on the results of Survey 2. The Delphi panel reached consensus that RH imaging is likely to improve the current risk stratification algorithms and help differentiate risk levels in patients at intermediate risk. Tricuspid annular plane systolic excursion, right ventricular fractional area change, right atrial area, tricuspid regurgitation, inferior venae cavae diameter, and pericardial effusion should be part of routine echocardiography in PAH. Cardiac magnetic resonance imaging is valuable but limited by cost and access. A pattern of abnormal RH imaging results should prompt consideration of hemodynamic evaluation and possible treatment escalation. RH imaging is an important tool for decisions about treatment escalation in PAH, but systematically collected evidence is needed to clarify its role.

20 November 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
Anjali VaidyaAnjali Vaidya
Anjali Vaidya
MSMargaret R. Sketch
Margaret R. Sketch
MBMeredith Broderick
Meredith Broderick
OSOksana A. Shlobin
Oksana A. Shlobin
Background: Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin therapy use among patients at intermediate risk according to the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 2.0 four-strata risk assessment model. Methods: This was a retrospective chart review and cross-sectional online survey of healthcare professionals (HCPs). Included patients were classified as intermediate-low or intermediate-high risk per COMPERA 2.0 between 2016 and 2020 (index visit), initiated on a parenteral prostacyclin any time following intermediate risk assessment, and had World Health Organization (WHO) Functional Class (FC), 6-minute walk distance (6MWD), and B-type natriuretic peptide/N-terminal pro B-type natriuretic peptide (BNP/NT-proBNP) assessments at index and first comprehensive follow-up visits (follow-up). Results: A total of 139 HCPs (53% community-based, 47% Pulmonary Hypertension Care Center-based) participated in the survey and provided 350 patient records; among these, mean age (SD) was 54.1 (15.3) years and 52% were female. Median (IQR) time from parenteral prostacyclin initiation to follow-up was 3.0 months (2.0, 7.0). At parenteral prostacyclin initiation for the 280 patient records with available COMPERA 2.0 assessments, 62% of patients were intermediate-high risk, 33% were intermediate-low risk and 3% were low risk, improving to 38%, 53%, and 8%, respectively, at follow-up. Conclusions: Improvements were seen for the individual COMPERA 2.0 risk calculator parameters and for several other clinical parameters. Findings from this study substantiate recent guidelines suggesting earlier use of this treatment in intermediate-risk patients with PAH. Clinical trial number: Not applicable.

1 May 2019
Verified
Conference Paper
Closed access
VBV. Balasubramanian
V. Balasubramanian
LML. Melendres-Groves
L. Melendres-Groves
ZSZ. Safdar
Z. Safdar
MBM. Broderick
M. Broderick
MSM. Sketch
M. Sketch
ANA. Nelsen
A. Nelsen

19 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MSMargaret R. Sketch
Margaret R. Sketch
DSDaniel Sauerstrom
Daniel Sauerstrom
ALAllison Marie Lange
Allison Marie Lange
JDJane Hall Diehl
Jane Hall Diehl
Background The Remunity Pump for Remodulin (treprostinil) Injection is an infusion system indicated for use with subcutaneous treprostinil. Objective The objective was to assess the stability of diluted treprostinil sodium stored in Remunity pump cassettes. Methods Treprostinil’s chemical and physical stability were assessed over a 76-hour period at 40 degrees Celsius and 75% relative humidity after dilution to 0.01 mg/mL in sterile water for injection and 0.9% sodium chloride. Analyses were conducted via visual inspection, pH measurement, and a stability-indicating high-performance liquid chromatographic assay. Results At all time points, the treprostinil samples were consistently clear, colorless, and free of visible particulate matter, with pH levels 6.0-7.0. All assays were within 90.0%-110.0% of the label claim, with minimal variation. Conclusions Treprostinil diluted to 0.01 mg/mL was stable in Remunity pump cassettes for up to 76 hours at elevated temperature and humidity. No notable changes from label claim concentration values were observed.